(Press-News.org) New Rochelle, NY, December 20, 2012—Small interfering RNAs (siRNAs) are a potent new drug class that can silence a disease-causing gene, but delivering them to a target cell can be challenging. An innovative delivery approach that dramatically increases the efficacy of an siRNA drug targeted to the liver and has made it possible to test the drug in non-human primates is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers (http://www.liebertpub.com). The article is available on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).
In the article "Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo" (http://online.liebertpub.com/doi/full/10.1089/nat.2012.0389) Wong and colleagues from Arrowhead Madison Inc. (Madison, WI) present a novel strategy to overcome the difficulty in delivering high levels of a gene knockdown siRNA drug to liver cells. While the cholesterol-conjugated siRNA drug is taken up preferentially by the liver, it is encapsulated in membrane-bound globules called endosomes and cannot reach the cells' DNA to exert its gene silencing effect. The researchers co-injected a polymer with the drug that also targets the liver and, once inside liver cells, breaks open the endosomes, releasing the siRNA drug.
"The promise of siRNAs is as strong as ever and is becoming even more so with progress in delivering these molecules to the right place at the right time," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "The work by Wong and colleagues is another important step towards realizing this promise."
INFORMATION:
Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, DukeUniversity Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD, SomaLogic, Boulder, CO.
About the Journal
Nucleic Acid Therapeutics (http://www.liebertpub.com/nat) is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society (http://www.oligotherapeutics.org). Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).
About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Genetic Testing and Molecular Biomarkers, ASSAY and Drug Development Technologies, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. publishers website (http://www.liebertpub.com).
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: (914) 740-2100
(800) M-LIEBERT
Fax: (914) 740-2101
Targeted gene silencing drugs are more than 500 times more effective with new delivery method
2012-12-21
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Researchers discover genetic basis for eczema, new avenue to therapies
2012-12-21
CORVALLIS, Ore. – Researchers at Oregon State University today announced the discovery of an underlying genetic cause of atopic dermatitis, a type of eczema most common in infancy that also affects millions of adults around the world with dry, itchy and inflamed skin lesions.
The findings were just published in PLoS ONE, a professional journal, and may set the stage for new therapeutic approaches to this frustrating syndrome, which is difficult to treat and has no known cure. Eczema is also related to, and can sometimes cause asthma, a potentially deadly immune dysfunction.
Pharmaceutical ...
Extending steroid treatment does not benefit children with hard-to-treat kidney disease
2012-12-21
Highlights
Six months of steroid treatment in children with nephrotic syndrome did not reduce relapse rates or side effects compared with three months of treatment.
Because many children with nephrotic syndrome face frequent relapses, future research should focus on preventing relapses through new treatment strategies.
Nephrotic syndrome has an estimated incidence of two to seven cases per 100,000 children and a prevalence of nearly 16 cases per 100,000.
Washington, DC (December 20, 2012) — Extending steroid treatment for the most common form of kidney disease ...
New target for treating prediabetes in patients with kidney disease
2012-12-21
Highlights
Retention of certain compounds that are normally excreted by the kidneys may cause insulin resistance, or prediabetes, in kidney disease patients.
When mice with kidney disease were treated with a prebiotic that reduces blood levels of these compounds, insulin resistance and lipid abnormalities were prevented.
Washington, DC (December 20, 2012) —Insulin resistance, or prediabetes, in individuals with kidney disease may be caused by the progressive retention of certain compounds that are normally excreted by the kidneys in healthy individuals, ...
Science's Breakthrough of the Year: Discovery of the Higgs boson
2012-12-21
The observation of an elusive sub-atomic particle, known as the Higgs boson, has been heralded by the journal Science as the most important scientific discovery of 2012. This particle, which was first hypothesized more than 40 years ago, holds the key to explaining how other elementary particles (those that aren't made up of smaller particles), such as electrons and quarks, get their mass.
In addition to recognizing the detection of this particle as the 2012 Breakthrough of the Year, Science and its international nonprofit publisher, AAAS, have identified nine other ...
Wallace's century-old map of natural world updated
2012-12-21
Until today, Alfred Russell Wallace's century old map from 1876 has been the backbone for our understanding of global biodiversity. Thanks to advances in modern technology and data on more than 20,000 species, scientists from University of Copenhagen have now produced a next generation map depicting the organisation of life on Earth. Published online in Science Express today, the new map provides fundamental information regarding the diversity of life on our planet and is of major significance for future biodiversity research.
An essential question in understanding life ...
Unlocking new talents in nature
2012-12-21
PASADENA, Calif.—Protein engineers at the California Institute of Technology (Caltech) have tapped into a hidden talent of one of nature's most versatile catalysts. The enzyme cytochrome P450 is nature's premier oxidation catalyst—a protein that typically promotes reactions that add oxygen atoms to other chemicals. Now the Caltech researchers have engineered new versions of the enzyme, unlocking its ability to drive a completely different and synthetically useful reaction that does not take place in nature.
The new biocatalysts can be used to make natural products—such ...
To outsmart malarial drug resistance, research team develops new whole-plant strategy
2012-12-21
AMHERST, Mass. – Malaria brings misery and death to millions in the developing world each year, and fighting it keeps medical researchers up at night because the mosquito-borne parasite Plasmodium falciparum, which causes the deadliest form of the disease, has developed resistance to every drug thrown at it. Resistance has cut short the useful life of nearly every therapy tried so far, experts say.
But now molecular parasitologist Stephen Rich at the University of Massachusetts Amherst has led a research team who report a promising new low-cost combined therapy with a ...
New MRI analysis useful in predicting stroke complications caused by clot-busters
2012-12-21
Johns Hopkins researchers have developed a new way of looking at standard MRI scans that more accurately measures damage to the blood-brain barrier in stroke victims, a process they hope will lead to safer, more individualized treatment of blood clots in the brain and better outcomes.
The blood-brain barrier is a unique shielding of blood vessels that limits the passage of molecules from the blood stream into the brain. Without it, the brain is open to infection, inflammation and hemorrhage. Ischemic stroke patients are at risk of bleeding into the brain when there is ...
Research reveals new drug target urgently needed for tuberculosis therapy
2012-12-21
One third of the world is infected with the bacterium that causes tuberculosis (TB), a disease that is increasingly difficult to treat because of wide spread resistance to available drugs. Researchers from the Institute of Pharmacology and Structural Biology (CNRS, Université de Toulouse) in Toulouse (France) have identified a fresh target to develop new drugs for TB. The study, published in the Open Access journal PLOS Pathogens, shows why the target will be important in developing new TB treatments.
The deadliest form of human tuberculosis is caused by Mycobacterium ...
Brain imaging insight into cannabis as a pain killer
2012-12-21
The pain relief offered by cannabis varies greatly between individuals, a brain imaging study carried out at the University of Oxford suggests.
The researchers found that an oral tablet of THC, the psychoactive ingredient in cannabis, tended to make the experience of pain more bearable, rather than actually reduce the intensity of the pain.
MRI brain imaging showed reduced activity in key areas of the brain that substantiated the pain relief the study participants experienced.
'We have revealed new information about the neural basis of cannabis-induced pain relief,' ...